Search hospitals > California > Sacramento
University of California Davis Comprehensive Cancer Center
Claim this profileSacramento, California 95817
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
870 reported clinical trials
40 medical researchers
Summary
University of California Davis Comprehensive Cancer Center is a medical facility located in Sacramento, California. This center is recognized for care of Cancer, Lung Cancer, Tumors, Non-Small Cell Lung Cancer, Recurrence and other specialties. University of California Davis Comprehensive Cancer Center is involved with conducting 870 clinical trials across 782 conditions. There are 40 research doctors associated with this hospital, such as Marcio H. Malogolowkin, Edward J. Kim, Joseph M. Tuscano, and Jonathan W. Riess.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Marcio H. MalogolowkinUniversity of California Davis Comprehensive Cancer Center7 years of reported clinical research
Expert in Tumors
Expert in Cancer
39 reported clinical trials
86 drugs studied
Edward J. KimUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Studies Cancer
Studies Adenocarcinoma
30 reported clinical trials
68 drugs studied
Joseph M. TuscanoUniversity of California Davis Comprehensive Cancer Center5 years of reported clinical research
Expert in Lymphoma
Studies B-Cell Lymphoma
19 reported clinical trials
37 drugs studied
Jonathan W. RiessUniversity of California Davis Comprehensive Cancer Center4 years of reported clinical research
Expert in Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
30 drugs studied
Clinical Trials running at University of California Davis Comprehensive Cancer Center
Breast Cancer
Cancer
Lung Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Tumors
Ovarian Cancer
Bladder Cancer
Lymphoma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of California Davis Comprehensive Cancer Center?
University of California Davis Comprehensive Cancer Center is a medical facility located in Sacramento, California. This center is recognized for care of Cancer, Lung Cancer, Tumors, Non-Small Cell Lung Cancer, Recurrence and other specialties. University of California Davis Comprehensive Cancer Center is involved with conducting 870 clinical trials across 782 conditions. There are 40 research doctors associated with this hospital, such as Marcio H. Malogolowkin, Edward J. Kim, Joseph M. Tuscano, and Jonathan W. Riess.
Where is University of California Davis Comprehensive Cancer Center located?
**UC Davis Comprehensive Cancer Center**
- **Address:** 2279 45th Street, Suite 1600, Sacramento, CA 95817.
- **Drop-off:** Main entrance on 45th Street.
- **Parking:** Available in Lot 4, behind the Cancer Center.
Who should I call to ask about financial aid or insurance network?
**University of California Davis Comprehensive Cancer Center - Financial Assistance and Insurance Inquiries**
- **Contact for Financial Assistance:** Reach out at 916-734-2293 (4-2293 on a hospital phone) from 8 a.m. to 4 p.m. or via email at hs-patientbilling@ucdavis.edu.
- **Insurance-Related Inquiries:** Use the same contact details as for financial assistance.
- **Supportive Oncology Contact:** Silvia Molina is available at 916-734-0461 or scmolina@ucdavis.edu for support.
What insurance does University of California Davis Comprehensive Cancer Center accept?
The University of California Davis Comprehensive Cancer Center accepts a wide range of health insurance plans, including Medicare, Medi-Cal, and most major health plans and insurance. Patients should contact the New Patient Referral Office at 916-703-5210 or 800-362-5566 to confirm if their specific insurance plan is accepted. It's crucial to verify with both the patient's insurance provider and the cancer center about prior authorization for services and potential charges not covered by insurance.
What awards or recognition has University of California Davis Comprehensive Cancer Center received?
The UC Davis Comprehensive Cancer Center, located in Sacramento, California, is recognized by the National Cancer Institute for its significant contributions to cancer research and patient care, receiving over $100 million in research funding annually. As an integral part of the UC Davis Medical Center, it provides access to more than 150 clinical trials and involves over 280 scientists in research programs that focus on biomedical technology, molecular oncology, and addressing cancer health disparities.